Atezolizumab Suppliers & Bulk Manufacturers
Available Forms: Intravenous infusion
Available Strengths: 1200 mg/20 mL
Reference Brands: Tecentriq® (EU & US)
Category: Oncology Cancer Care
Atezolizumab (Tecentriq®) is a PD-L1 checkpoint inhibitor used in urothelial carcinoma, NSCLC, and triple-negative breast cancer. Available as sterile IV infusion vials (1200 mg/20 mL), manufactured under EU-GMP and USFDA standards. Ideal for B2B supply, hospital tenders, and licensing. Atezolizumab is available in Intravenous infusion and strengths such as 1200 mg/20 mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Atezolizumab is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Atezolizumab can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Atezolizumab (Tecentriq®) is a PD-L1 immune checkpoint inhibitor indicated for urothelial carcinoma, NSCLC, and triple-negative breast cancer. Provided as sterile intravenous infusion vials (1200 mg/20 mL), Atezolizumab is produced under EU-GMP and USFDA standards. Offered for B2B supply, contract manufacturing, and licensing, it supports hospital tenders and oncology distributors with full regulatory documentation. This monoclonal antibody restores anti-tumor immunity by blocking PD-L1, making it a vital immuno-oncology therapy in US and European cancer treatment portfolios.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Atezolizumab is used to treat several types of cancer, including non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, triple-negative breast cancer, and urothelial carcinoma. It works by blocking the PD-L1 protein on tumor cells, helping the immune system detect and destroy cancer cells more effectively.
Atezolizumab is a humanized monoclonal antibody created using recombinant DNA technology. It is produced from genetically engineered Chinese hamster ovary (CHO) cells that express an antibody specifically targeting PD-L1, a protein found on tumor and immune cells.
The trade name of Atezolizumab is Tecentriq.
Atezolizumab is developed and manufactured by Genentech, Inc., which is a member of the Roche Group, a global leader in cancer immunotherapy.
The generic name of the product is Atezolizumab.
The brand name of the product is Tecentriq.
Atezolizumab (Tecentriq) is manufactured by Genentech, Inc. in the United States, and additional manufacturing and packaging for international supply are handled at Roche production facilities in Europe and other regions.
Related Products
Tafasitamab‑Cxix
Strength:
200 mg
Form: Injection
Reference Brands: Monjuvi (USA), Minjuvi (EU)
View Details
Dordaviprone Hydrochloride
Strength:
125 mg
Form: Capsules
Reference Brands: Modeyso (USA)
View Details
Quick Response Guaranteed | Verified Suppliers
